March 1999
AIDS Patient Care & STDs;Mar1999, Vol. 13 Issue 3, p202
Academic Journal
Announces the recruitment of HIV patients with CD4 cell counts above 500 for a phase II placebo-controlled study of low-dose cyclosporine. Anecdotal reports of the potential of the immunosuppressant as an HIV treatment; Duration of the trial.


Related Articles

  • Uptake of antiretroviral treatment among people living with HIV in London: ethnicity, gender and sexual orientation. Elford, J.; Ibrahim, F.; Bukutu, C.; Anderson, J. // Sexually Transmitted Infections;Jun2008, Vol. 84 Issue 3, p176 

    Objective: To examine, by ethnicity, gender and sexual orientation, uptake of antiretroviral treatment among people living with HIV in London. Methods: Between June 2004 and June 2005, 1687 people living with HIV (73% response) receiving treatment and care in North East London National Health...

  • Elvitegravir non-inferior to raltegravir in treatment-experienced patients.  // Infectious Disease News;Aug2011, Vol. 24 Issue 8, p12 

    The article focuses on a study which compared the effectiveness of once-daily elvitegravir and twice-daily raltegravir in treating HIV-1 infected patients.

  • Chapter #4: Controlling HIV and AIDS. Gedatus, Gustav Mark // HIV & AIDS (0-7368-0281-9);2000, p28 

    The chapter focuses on the importance of knowing one's HIV status to control its effects and to protect others from the virus. Testing for HIV can be done confidentially or anonymously for complete privacy. HIV-positive people need to eat right, exercise, get plenty of rest, and avoid tobacco,...

  • The Virologic and Immunologic Effects of Cyclosporine as an Adjunct to Antiretroviral Therapy in Patients Treated during Acute and Early HIV-1 Infection. Markowitz, Martin; Vaida, Florin; Hare, C. Bradley; Boden, Daniel; Mohri, Hiroshi; Hecht, Frederick M.; Kalayjian, Robert C.; Conrad, Ann; Mildvan, Donna; Aberg, Judith; Hogan, Christine; Kilby, J. Michael; Balfour Jr., Henry H.; Schafer, Kim; Richman, Douglas; Little, Susan // Journal of Infectious Diseases;5/1/2010, Vol. 201 Issue 9, p1298 

    Acute human immunodeficiency virus type 1 (HIV-1) infection is characterized by high levels of immune activation. Immunomodulation with cyclosporine combined with antiretroviral therapy (ART) in the setting of acute and early HIV-1 infection has been reported to result in enhanced immune...

  • Patient Adherence To HAART Regimens: Challenges For Physician Assistants And Health Care Providers. Day, Marvin // Internet Journal of Academic Physician Assistants;2003, Vol. 3 Issue 1, p42 

    Patients often adhere incompletely and inadequately to highly active antiretroviral therapy (HAART) regimens used in the treatment of HIV infection. This permits the emergence of HIV variants that are resistant to current treatment. The physician assistant often assumes the responsibility for...

  • HIV-1 rebound after anti-retroviral therapy. Ho, David D.; Zhang, Linqi // Nature Medicine;Jul2000, Vol. 6 Issue 7, p736 

    Compares the genotype of rebounding virus with that in the latent reservoir in HIV-1 patients after highly active anti-retroviral therapy. Genetic technique used to study the relationship; Dynamics of the interplay between productive and latent HIV-1 infection; Control of latent reservoir by...

  • Early Treatment For HIV Can Boost Survival Significantly. Parham, Marti // Jet;11/17/2008, Vol. 114 Issue 19, p48 

    The article discusses a research study by the University of Washington that found a link between early treatment of HIV and an increased survival rate. The author states that HIV patients who did not receive treatment soon after they were diagnosed were 70% more likely to die than those who...

  • More research needed to determine risks of efavirenz treatment among children.  // Infectious Disease News;Jul2014, Vol. 27 Issue 7, p46 

    The article reports that a review in the "Journal of Pediatric Health, Medicine and Therapeutics" stressed the need for more research on the actual risks of treating children with HIV-1 with efavirenz.

  • Early Virologic Failure in a Pilot Study Evaluating the Efficacy of Therapy Containing Once-Daily Abacavir, Lamivudine, and Tenofovir DF in Treatment-Naive HIV-Infected Patients. Khanlou, Homayoun; Yeh, Vivian; Guyer, Bill; Farthing, Charles // AIDS Patient Care & STDs;Mar2005, Vol. 19 Issue 3, p135 

    Previous investigational data using abacavir (ABC), lamuvidine (3TC), and zidovudine has suggested the possibility of triple nucleoside analogue reverse transcriptase inhibitors (NRTI) therapy as an option in the treatment of HIV infection. We performed a pilot study to assess the potency of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics